Gyre Therapeutics Inc
NASDAQ:GYRE

Watchlist Manager
Gyre Therapeutics Inc Logo
Gyre Therapeutics Inc
NASDAQ:GYRE
Watchlist
Price: 7.4 USD -2.25% Market Closed
Market Cap: 672.6m USD

Operating Margin
Gyre Therapeutics Inc

11.2%
Current
-396%
Average
-4.7%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.2%
=
Operating Profit
12m
/
Revenue
107.3m

Operating Margin Across Competitors

No Stocks Found

Gyre Therapeutics Inc
Glance View

Gyre Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2006-04-12. Gyre Therapeutics, Inc., formerly Catalyst Biosciences, Inc., is a biotechnology company. The firm is focused on organ fibrosis and inflammatory diseases. The firm is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The firm is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase 3 trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase 1 trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.

GYRE Intrinsic Value
25.67 USD
Undervaluation 71%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.2%
=
Operating Profit
12m
/
Revenue
107.3m
What is the Operating Margin of Gyre Therapeutics Inc?

Based on Gyre Therapeutics Inc's most recent financial statements, the company has Operating Margin of 11.2%.

Back to Top